Publications

Publications

American Association for the Study of Liver Disease (AASLD)

November 10-14, 2023 | Boston, MA

Safety and Tolerability of Continuous Infusion Terlipressin (BIV201) in Patients With Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study

Clinical Trials on Alzheimer's Disease conference (CTAD)

October 24 – 27, 2023 | Boston, MA

Oral Presentation: Clinical Outcomes From a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects With Mild to Moderate Probable Alzheimer’s Disease

American Neurological Association Annual Meeting

September 11-13, 2023 | Philadelphia, PA

Metabolic Dysregulation in Probable Alzheimer’s Disease

International Congress of Parkinson’s Disease and Movement Disorders

August 27-31, 2023 | Copenhagen, Denmark

Oral Presentation: Effects of NE3107 Anti-inflammatory Treatment on Motor Activity and Neurodegenerative Features of Parkinson’s Disease in a Marmoset Monkey Model

Oral Presentation: Effects of NE3107 Anti-inflammatory Treatment on Motor Activity and Neurodegenerative Features of Parkinson’s Disease in a Marmoset Monkey Model

Safety and Pharmacokinetics of Anti-Inflammatory NE3107 Treatment in Carbidopa/Levodopa-TreatedPatients With Parkinson’s Disease: A Phase 2a, Double-Blind, Placebo-Controlled Study

A Randomized, Phase 2a, Double-Blind, Placebo-Controlled Clinical Trial With NE3107 Adjunctive to Carbidopa/Levodopa in Patients With Parkinson’s Disease

Alzheimer’s Association International Conference

July 16-20, 2023 | Amsterdam, Netherlands

Treatment-Induced Epigenetic Modifications in MCI and Probable Alzheimer’s Disease

83rd Scientific Sessions of the American Diabetes Association

June 23-26, 2023 | San Diego, CA

Metabolic Dysregulation in Probable Alzheimer’s Disease

Metabolic Dysregultion in Probable Alzheimer’s Disease

The International Liver Congress (EASL)

June 21-24 | Vienna, Austria

Safety and Efficacy of Continuous Infusion Terlipressin (BIV201) in Patients With Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study

2023 World Congress on Parkison’s Disease and Related Disorders (IAPRD)

May 13-16, 2023 | Chicago, IL

Rationale for a Potentially Pivotal Study of NE3107 in Parkinson’s Disease

78th Annual Scientific Convention of the Society of Biological Psychiatry (SOBP)

April 27-29, 2023 | San Diego, CA 

Effects of NE3107 on Depression and Multi-modal Outcomes in a Phase 2, Open-label Study in Patients With Cognitive Decline Due to Degenerative Dementias

Effects of NE3107 on Depression and Multi-modal Outcomes in a Phase 2, Open-label Study in Patients With Cognitive Decline Due to Degenerative Dementias

2023 American Academy of Neurology (AAN) Annual Meeting

April 22 – 27, 2023 | Boston, MA

Safety, Tolerability, and Efficacy of NE3107 From a Phase 2, Double-Blind, Placebo-Controlled Study in Levodopa/Carbidopa-Treated Patients With Parkinson’s Disease

Multi-Modal Correlation Analyses From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline
Due to Degenerative Dementias

Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias

2023 International on Alzheimer's and Parkinson's Disease and Related Neurological Disorders (AD / PD) Conference

March 28 – April 2, 2023 | Gothenburg, Sweden

Effect of NE3107 on the Pharmacokinetics Profile of Carbidopa/Levodopa in Patients With Parkinson’s Disease: A Phase 2, Double-Blind, Placebo-Controlled Study

Safety, Tolerability, and Efficacy of NE3107 From a Phase 2, Double-Blind, Placebo-Controlled Study in Levodopa/Carbidopa-Treated Patients With Parkinson’s Disease

2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference

November 29 – December 2, 2022 | San Francisco, California

Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias

Biomarker Assessments From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias

Neuroimaging Data From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias